Search clinical trials for: REGN3470-3471-3479

Total 1082 results

Regeneron Pharmaceuticals
Department of Health and Human Services

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Available

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Ebola Virus Disease
Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Hungary, Korea, Republic of, Germany, Japan, Poland, Australia, Canada, Czechia, Spain, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

Healthy Volunteers

Belgium
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Merkel Cell Carcinoma

United States, Australia, Canada, France, Italy, New Zealand, Spain, Sweden
Regeneron Pharmaceuticals

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Healthy Volunteers

New Zealand
Regeneron Pharmaceuticals

Terminated

Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers

Healthy Volunteer

Belgium
Regeneron Pharmaceuticals

Withdrawn

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodyplasia Ossificans Progressiva (FOP) | Heterotopic Ossification (HO)
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

Asthma | Moderate Asthma

United Kingdom
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals

Withdrawn

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis
Regeneron Pharmaceuticals

Terminated

Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers

Healthy Volunteer

United States
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (LUMINA-1)

Fibrodysplasia Ossificans Progressiva

United States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
MedSIR

Terminated

Checkpoint Blockade in COVID-19 Pandemic (COPERNICO)

COVID-19 | Pneumonia, Viral

Spain
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Completed

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Brain Cancer

United States
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Singapore, Australia, France, Germany, Italy, United Kingdom
Sarcoma Alliance for Research through Collaboration
Merck Sharp & Dohme LLC

Completed

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Soft Tissue Sarcoma | Bone Sarcoma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer (PANACEA)

Metastatic Breast Cancer

France, Austria, Belgium, Australia, Italy
Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Korea, Republic of, Belgium, Czechia, Germany, Poland, Spain
Institut de Recherches Internationales Servier
Merck Sharp & Dohme LLC

Recruiting

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma

Astrocytoma

United States
Eileen Connolly
Merck Sharp & Dohme LLC

Recruiting

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT)

Triple Negative Breast Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)

Non-Small-Cell Lung Cancer
Nasser Hanna, M.D.
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Terminated

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Genital Neoplasms, Female | Testicular Neoplasms | Genital Neoplasms, Male | Ovarian Neoplasms | Mediastinal Neoplasms | Germ Cell Neoplasms | Non Seminomatous Germ Cell Tumors

United States
PETHEMA Foundation
Merck Sharp & Dohme LLC; Adknoma Health Research

Completed

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Multiple Myeloma

Spain
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

MSI Positive Colorectal Cancer | MSI Negative Colorectal Cancer | MSI Positive Non-Colorectal Cancers

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)

Esophageal Carcinoma | Esophagogastric Junction Carcinoma
St. Louis University

Completed

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NeoPembroMel)

Melanoma | Metastatic Melanoma | Stage IV Melanoma | Unresectable Malignant Neoplasm | Stage III Melanoma

United States
University Hospital, Ghent

Completed

Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

Belgium
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) (PRIMUS)

Metastatic Squamous Non-small Cell Lung Cancer

Germany
Erasmus Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab (RESPONDER)

Biomarkers | Transitional Cell Carcinoma of the Bladder

Netherlands
Fox Chase Cancer Center
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Medullary Thyroid Cancer (MTC)

United States
Center Trials & Treatment

No longer available

Expanded Access for Pembrolizumab (MK-3475)

Glioblastoma Multiforme | Melanoma (Skin) | Melanoma Recurrent | Glioma of Brain | Glioblastoma by Gene Expression Profile

Hong Kong, Belarus, Tajikistan, Uzbekistan
Kindai University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab as Neoadjuvant Treatment in HCC

Hepatocellular Carcinoma
Fox Chase Cancer Center
Merck Sharp & Dohme LLC

Terminated

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Lymphoma, T-Cell, Peripheral

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Melanoma | Lymphoma | Head and Neck Cancer | Gastric Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Lung Cancer | Bladder Cancer | Endometrial Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | UC (Urothelial Cancer) | Microsatellite-instability (MSI) High Colorectal...

United States
Assistance Publique - Hôpitaux de Paris

Completed

Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin (CARSKIN)

Carcinoma, Squamous Cell

France
Samsung Medical Center

Completed

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Ovarian Neoplasms
Affimed GmbH
Merck Sharp & Dohme LLC; The Leukemia and Lymphoma Society

Completed

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)

Melanoma | Carcinoma, Non-Small-Cell Lung

India
Lynn Feun, MD
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Aduro Biotech, Inc.
Merck Sharp & Dohme LLC

Terminated

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

Malignant Pleural Mesothelioma

United States
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1)

Castration-resistant Prostate Cancer

United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Metastatic Castration-resistant Prostate Cancer
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)

Neoplasms | Colorectal Cancer

United States, Canada
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States

Search clinical trials for: REGN3470-3471-3479

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations